These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33400975)

  • 41. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model.
    Haagmans BL; Noack D; Okba NMA; Li W; Wang C; Bestebroer T; de Vries R; Herfst S; de Meulder D; Verveer E; van Run P; Lamers MM; Rijnders B; Rokx C; van Kuppeveld F; Grosveld F; Drabek D; Geurts van Kessel C; Koopmans M; Bosch BJ; Kuiken T; Rockx B
    J Infect Dis; 2021 Jun; 223(12):2020-2028. PubMed ID: 34043806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
    Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody Therapy for COVID-19: Categories, Pros, and Cons.
    Zare Marzouni H; Rahbar M; Seddighi N; Nabizadeh M; Meidaninikjeh S; Sabouni N
    Viral Immunol; 2022 Oct; 35(8):517-528. PubMed ID: 36201297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.
    Cruz-Teran C; Tiruthani K; McSweeney M; Ma A; Pickles R; Lai SK
    Adv Drug Deliv Rev; 2021 Feb; 169():100-117. PubMed ID: 33309815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19.
    Boggiano C; Eisinger RW; Lerner AM; Anderson JM; Woodcock J; Fauci AS; Collins FS
    Ann Intern Med; 2022 Jan; 175(1):119-126. PubMed ID: 34724404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic.
    Farcet MR; Karbiener M; Schwaiger J; Ilk R; Kreil TR
    J Infect Dis; 2022 Oct; 226(8):1357-1361. PubMed ID: 33725725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coronavirus disease 2019 management.
    Wilson KC
    Curr Opin Pulm Med; 2021 May; 27(3):169-175. PubMed ID: 33606409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
    Hopwood AJ; Jordan-Villegas A; Gutierrez LD; Cowart MC; Vega-Montalvo W; Cheung WL; McMahan MJ; Gomez MR; Laham FR
    J Pediatric Infect Dis Soc; 2021 May; 10(5):691-694. PubMed ID: 33306130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals.
    Chen J; Lu H
    Biosci Trends; 2021 May; 15(2):126-128. PubMed ID: 33746183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. COVID-19: benefits and risks of passive immunotherapeutics.
    Gupta A; Karki R; Dandu HR; Dhama K; Bhatt ML; Saxena SK
    Hum Vaccin Immunother; 2020 Dec; 16(12):2963-2972. PubMed ID: 32962524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.
    Maciorowski D; Ogaugwu C; Durvasula SR; Durvasula R; Kunamneni A
    SLAS Discov; 2021 Mar; 26(3):311-329. PubMed ID: 33319627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
    Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
    Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The use of immunoglobulins and monoclonal antibodies against COVID-19].
    Popadyuk EE; Sizikova TE; Khmelev AL; Timofeev MA; Lebedev VN; Borisevich SV
    Vopr Virusol; 2024 May; 69(2):119-126. PubMed ID: 38843018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.
    Tirnea L; Bratosin F; Vidican I; Cerbu B; Turaiche M; Timircan M; Margan MM; Marincu I
    Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33799535
    [No Abstract]   [Full Text] [Related]  

  • 56. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.
    Lang-Meli J; Fuchs J; Mathé P; Ho HE; Kern L; Jaki L; Rusignuolo G; Mertins S; Somogyi V; Neumann-Haefelin C; Trinkmann F; Müller M; Thimme R; Umhau M; Quinti I; Wagner D; Panning M; Cunningham-Rundles C; Laubner K; Warnatz K
    J Clin Immunol; 2022 Feb; 42(2):253-265. PubMed ID: 34893946
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential mechanisms of action of convalescent plasma in COVID-19.
    Franchini M; Glingani C; Liumbruno GM
    Diagnosis (Berl); 2021 Nov; 8(4):413-420. PubMed ID: 33652503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019.
    Hartog N; Holsworth A; Rajasekaran S
    Ann Allergy Asthma Immunol; 2021 Feb; 126(2):122-123. PubMed ID: 33161152
    [No Abstract]   [Full Text] [Related]  

  • 59. Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review.
    Franchini M; Prefumo F; Grisolia G; Bergamini V; Glingani C; Pisello M; Presti F; Zaffanello M
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34206468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy.
    Kędzierska-Kapuza K; Zielińska D; Matejak-Górska M; Durlik M
    Transplant Proc; 2021 May; 53(4):1194-1201. PubMed ID: 33892930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.